295 related articles for article (PubMed ID: 32512015)
1. Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.
Jepsen P; Kraglund F; West J; Villadsen GE; Sørensen HT; Vilstrup H
J Hepatol; 2020 Nov; 73(5):1030-1036. PubMed ID: 32512015
[TBL] [Abstract][Full Text] [Related]
2. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study.
Jepsen P; Ott P; Andersen PK; Sørensen HT; Vilstrup H
Ann Intern Med; 2012 Jun; 156(12):841-7, W295. PubMed ID: 22711076
[TBL] [Abstract][Full Text] [Related]
3. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
[TBL] [Abstract][Full Text] [Related]
4. The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study.
Jepsen P; Lash TL; Vilstrup H
Liver Int; 2016 Nov; 36(11):1696-1703. PubMed ID: 27124269
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis.
Huang DQ; Tan DJH; Ng CH; Amangurbanova M; Sutter N; Lin Tay PW; Lim WH; Yong JN; Tang A; Syn N; Muthiah MD; Tan EXX; Dave S; Tay B; Majzoub AM; Gerberi D; Kim BK; Loomba R
Clin Gastroenterol Hepatol; 2023 May; 21(5):1169-1177. PubMed ID: 35940513
[TBL] [Abstract][Full Text] [Related]
6. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study.
Appel-da-Silva MC; Miozzo SA; Dossin IA; Tovo CV; Branco F; de Mattos AA
World J Gastroenterol; 2016 Dec; 22(46):10219-10225. PubMed ID: 28028370
[TBL] [Abstract][Full Text] [Related]
7. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study.
Nilsson E; Anderson H; Sargenti K; Lindgren S; Prytz H
Scand J Gastroenterol; 2019 Aug; 54(8):1027-1032. PubMed ID: 31389730
[No Abstract] [Full Text] [Related]
8. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: A nationwide cohort study.
Hallager S; Ladelund S; Kjaer M; Madsen LG; Belard E; Laursen AL; Gerstoft J; Røge BT; Grønbaek KE; Krarup HB; Christensen PB; Weis N
J Viral Hepat; 2018 Jan; 25(1):47-55. PubMed ID: 28750141
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
N'Kontchou G; Paries J; Htar MT; Ganne-Carrie N; Costentin L; Grando-Lemaire V; Trinchet JC; Beaugrand M
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1062-8. PubMed ID: 16844421
[TBL] [Abstract][Full Text] [Related]
11. Impact of hepatitis B and C virus infection on the clinical prognosis of alcoholic liver cirrhosis.
Yamanaka T; Shiraki K; Nakazaawa S; Okano H; Ito T; Deguchi M; Takase K; Nakano T
Anticancer Res; 2001; 21(4B):2937-40. PubMed ID: 11712790
[TBL] [Abstract][Full Text] [Related]
12. Men with biopsy-confirmed hepatocellular adenoma have a high risk of progression to hepatocellular carcinoma: A nationwide population-based study.
Bossen L; Grønbaek H; Lykke Eriksen P; Jepsen P
Liver Int; 2017 Jul; 37(7):1042-1046. PubMed ID: 28317318
[TBL] [Abstract][Full Text] [Related]
13. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
14. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark.
Sorensen HT; Friis S; Olsen JH; Thulstrup AM; Mellemkjaer L; Linet M; Trichopoulos D; Vilstrup H; Olsen J
Hepatology; 1998 Oct; 28(4):921-5. PubMed ID: 9755226
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
Yi SW; Choi JS; Yi JJ; Lee YH; Han KJ
Cancer; 2018 Jul; 124(13):2748-2757. PubMed ID: 29669170
[TBL] [Abstract][Full Text] [Related]
16. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection.
Uetake S; Yamauchi M; Itoh S; Kawashima O; Takeda K; Ohata M
Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):47S-51S. PubMed ID: 12960507
[TBL] [Abstract][Full Text] [Related]
17. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study.
West J; Card TR; Aithal GP; Fleming KM
Aliment Pharmacol Ther; 2017 Apr; 45(7):983-990. PubMed ID: 28144999
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
Fattovich G; Stroffolini T; Zagni I; Donato F
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S35-50. PubMed ID: 15508101
[TBL] [Abstract][Full Text] [Related]
19. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
20. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
